[
    [
        {
            "time": "",
            "original_text": "贝达药业(300558.SZ)收到CDE签发的关于盐酸恩沙替尼原料药和制剂的补充资料通知书",
            "features": {
                "keywords": [
                    "贝达药业",
                    "CDE",
                    "盐酸恩沙替尼",
                    "原料药",
                    "制剂",
                    "补充资料通知书"
                ],
                "sentiment_score": 0.2,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)收到CDE签发的关于盐酸恩沙替尼原料药和制剂的补充资料通知书",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【国盛医药张金洋团队】周观点：肝素到底是不是周期还是成长？——兼论全球肝素产业链重构",
            "features": {
                "keywords": [
                    "国盛医药",
                    "张金洋",
                    "肝素",
                    "周期",
                    "成长",
                    "产业链重构"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国盛医药张金洋团队】周观点：肝素到底是不是周期还是成长？——兼论全球肝素产业链重构",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]